Search
Allogene Therapeutics Inc
ALLOAdd to Watchlist
1.040USD
-0.050-4.59%
Close 11-06 16:00（ET）
359.31MMarket Cap
LossP/E TTM
Pre-market 08:01 (ET)1.070USD+0.030+2.88%
Pre-market 08:01 (ET)Today
-4.59%
5 Days
-11.86%
1 Month
-25.71%
6 Months
-54.39%
Year to Date
-24.09%
1 Year
-11.86%
Key Figures
1.090Open
1.130High
1.30MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.38%Turnover Ratio
1.090Prev. Close
0.980Low
1.35MTurnover
LossP/E Static
0.82P/B
0.00%Div Yield TTM
-38.45%ROA
4.46052wk High
0.11Volume Ratio
-257.59MNet Profit
345.49MShares
-0.7651EPS TTM
0.47Beta
-52.32%ROE
0.98052wk Low
19.27%Amplitude
100.00%Gross Margin
359.31MMarket Cap
3.00Reward/Risk
5.22%Risk Rate
Allogene Therapeutics Inc's Score
0.05vs previous score
Forecast8.50
Financial Health6.88
Technical5.07
Valuation Dimensions6.41
Institutional Confidence3.00
Risk Assessment4.71
Media Coverage
Coverage Level
Very Low
Very High
Neutral
Analyst Rating
Allogene Therapeutics Inc Technical Analysis
Technical Indicators
Strong sell
Summary
Strong sell
Moving Average
Strong sell
Allogene Therapeutics Inc Latest Earnings Call Transcripts
Allogene Therapeutics (ALLO) Q3 2026 Earnings Call: ALPHA3 Progress and ALLO-329 Data
Allogene Therapeutics Q3 2026 earnings call highlights ALPHA3 enrollment progress, 2027 milestones and upcoming ALLO-329 autoimmune disease data.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.15/-0.15
Revenue / Forecast
0.00/2.22K
Allogene Therapeutics Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolALLO
Number of employees226
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Pfizer Inc | 6.39% |
| TPG Capital, L.P. | 5.42% |
| Frazier Life Sciences Management, L.P. | 4.70% |
| Citadel Advisors LLC | 3.51% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 16.18% |
| Private Equity | 12.41% |
| Hedge Fund | 8.61% |
| Investment Advisor/Hedge Fund | 7.80% |
Related Instruments
-0.79%
+1.43%
+1.07%
-0.14%
+0.38%
-0.22%
+0.03%
-0.41%
+0.02%
-0.20%
+0.85%
-1.57%
-1.04%
+0.28%
+5.27%
-0.16%
+0.16%
-0.80%
+1.46%
+3.63%Popular Instruments
51879.000
+588.400 (+1.15%)
27240.600
+276.100 (+1.02%)
7445.300
+65.300 (+0.89%)
12797.000
-1.000 (-0.01%)
59200.000
+1058.000 (+1.82%)
6251.700
+111.100 (+1.81%)
86.732
-3.125 (-3.48%)
342.370
-1.800 (-0.52%)
186.640
+5.040 (+2.78%)
4122.740
+57.070 (+1.40%)
FAQs
What is the current price of Allogene Therapeutics Inc (ALLO)?
The current price of Allogene Therapeutics Inc (ALLO) is 1.04.
What is the symbol of Allogene Therapeutics Inc?
The ticker symbol of Allogene Therapeutics Inc is ALLO.
What is the 52-week high of Allogene Therapeutics Inc?
The 52-week high of Allogene Therapeutics Inc is 4.46.
What is the 52-week low of Allogene Therapeutics Inc?
The 52-week low of Allogene Therapeutics Inc is 0.98.
What is the market capitalization of Allogene Therapeutics Inc?
The market capitalization of Allogene Therapeutics Inc is 359.31M.
Is Allogene Therapeutics Inc (ALLO) currently rated as Buy, Hold, or Sell?
According to analysts, Allogene Therapeutics Inc (ALLO) has an overall rating of Buy, with a price target of 9.00.
What is the Earnings Per Share (EPS TTM) of Allogene Therapeutics Inc (ALLO)?
The Earnings Per Share (EPS TTM) of Allogene Therapeutics Inc (ALLO) is -0.77.